Niagen Bioscience Taps Evotec for Preclinical Development of Rare Disease Drug NB4168 — Niagen Bioscience, Inc.

Event summary

Niagen Bioscience has selected Evotec as a contract research organization to advance preclinical development of NB4168, its proprietary oral small-molecule candidate for Ataxia Telangiectasia (A-T).
Evotec will conduct pharmacokinetic and pharmacodynamic studies at its Verona, Italy campus using its INDiGO platform to streamline development.
NB4168 has demonstrated higher blood exposure compared with NR chloride in nonclinical studies, supporting its continued development.
Niagen Bioscience plans to submit an Investigational New Drug (IND) application to the FDA for NB4168.

The big picture

This collaboration with Evotec underscores Niagen Bioscience's strategic shift from consumer supplements to pharmaceutical development, targeting rare genetic diseases. The partnership leverages Evotec's integrated drug development platform to accelerate the preclinical timeline and reduce risks associated with bringing NB4168 to market. The focus on A-T, a disease with no approved treatments, positions Niagen Bioscience in a niche but high-impact therapeutic area.

What we're watching

Development Timeline: The pace at which Niagen Bioscience can generate the necessary data to support an IND application and initiate clinical trials for NB4168.
Bioavailability Advantage: Whether NB4168's demonstrated higher blood exposure compared with NR chloride will translate into meaningful clinical benefits for A-T patients.
Regulatory Pathway: How the FDA Rare Pediatric Disease Designation and EMA Orphan Medicinal Product Designation will influence the regulatory strategy and potential approval pathway for NB4168.